BIO-RAD LABORATORIES-A
BIONYSETrading Snapshot
- Day Range
- $377.69 โ $385.85
- 52-Week Range
- $236.73 โ $396.23
- Volume
- $2.43B
- Avg Volume
- $2.64B
- Shares Outstanding
- 26.9M
- Next Earnings
- Oct 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.58B
- Last Q Revenue
- $651M
- P/E Ratio
- 45.3
- P/S Ratio
- 3.9x
- EPS (TTM)
- $8.32
- Dividend Yield
- 0.00%
- Dilution (1yr)
- โ3.5%
Why Investors Own BIO
- โHigh-growth profile โ revenue up +27.5% YoY with expanding US Equity exposure.
- โHealthy economics โ 40% gross margin and 22% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BIO-RAD LABORATORIES-A
BIOAbout BIO-RAD LABORATORIES-A
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Analyst Ratings
โLatest News & Updates

BIO-key Partners with Al Majlis Group to Expand Identity Security Across Arabian Gulf
BIO-key (BKYI) Partners with Al Majlis Group, Founded by His Excellency Dherar Belhoul Al Falasi, to Expand Identity Security Across Arabian Gulf Region.

Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth
Bio-Rad Laboratories NYSE: BIO is pursuing a multi-year effort to improve growth, expand margins and strengthen free cash flow, with management emphasizing portfolio focus, operating discipline and a more selective appro

Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript

Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.

BIO-key Receives FIDO Alliance Full Certification for Passkey:YOUโข Authentication, Unlocking New Markets Including Agentic AI Authenticated Controls
HOLMDEL, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BIO-keyยฎ International, Inc. (NASDAQ: BKYI), a global provider of workforce and customer Identity and Access Management (IAM) software featuring passwordless, phoneless a

Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. L